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Available online 28 December 2015Prostate cancer (PCa) is the secondmost common cancer inmen. The AndrogenReceptor (AR) is themajor driver
of PCa and the main target of therapy in the advanced setting. AR is a nuclear receptor that binds the chromatin
and regulates transcription of genes involved in cancer cell proliferation and survival. In a study by Stelloo et al.
(1) we explored prostate cancer on the level of transcriptional regulation by means of Formaldehyde-Assisted
Isolation of Regulatory Elements and Chromatin Immunoprecipitation coupled withmassive parallel sequencing
(FAIRE-seq and ChIP-seq, respectively). We employed these data for the assessment of differences in transcrip-
tional regulation at distinct stages of PCa progression and to construct a prognostic gene expression classiﬁer. Ge-
nomics data includes FAIRE-seq data from normal prostate tissue as well as primary, hormone therapy resistant
andmetastatic PCa. Furthermore, ChIP-seq data fromprimary and resistant PCawere generated, alongwithmul-
tiple input controls. The data are publicly available through NCBI GEO database with accession number
GSE65478. Here we describe the genomics and clinical data in detail and provide comparative analysis of
FAIRE-seq and ChIP-seq data.








array typeIllumina Hiseq 2000 genome analyzerata format Raw: SRA study; processed: BED
xperimental
factorsNormal, primary and therapy resistant tumors, lymph node
metastasesxperimental
featuresFAIRE-seq and Androgen Receptor ChIP-seqonsent Leftover anonymized tissue (not traceable back to the patient
and not interfering with care and/or prognosis) used for
research purposes.mple source
locationSamples were from prostate cancer patients, treated at the
Erasmus University Medical Center (EMC; Rotterdam, The
Netherlands), The Netherlands Cancer Institute/Antoni van
Leeuwenhoek hospital (Amsterdam, The Netherlands).zwart@nki.nl (W. Zwart).
. This is an open access article underDirect link to deposited data https://www.ncbi.nlm.nih.gov/geo/
query/acc.cgi?acc=GSE65478
1. Experimental design, materials and methods
1.1. Clinical samples and experimental design
Fresh frozen tissue samples were obtained through postoperative
needle biopsies targeting both tumor and normal areas of prostatecto-
my specimens at The Netherlands Cancer Institute (Amsterdam, The
Netherlands). Tissue samples from androgen deprivation resistant tu-
mors (from transurethral resection of the prostate (TURP)) and lymph
node metastases were obtained from the Erasmus University Medical
Center (Rotterdam, The Netherlands). Slides stained with hematoxylin
and eosin (H&E) of the caseswere reviewed by our pathologists. Clinical
and pathological parameters of the selected patients are provided in
Table 1. Leftover anonymized tissue, which cannot be traced back to
the patient and does not interfere with care and/or prognosis, and
would have been discarded otherwise, has been used in accordance
with the Code of Conduct of the Federation of Medical Scientiﬁc
Societies in The Netherlands. NKI and ErasmusMC institutional medical
ethics committees have approved the study.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Patient and tumor characteristics of the selected samples.
Characteristic Number of patients
Normal Primary Resistant Metastasis
4 4 4 3
Treatment type
Untreated 3 4 0 2
Bicalutamide/cyproteron acetate 1 0 0 0
Bicalutamide/LHRH analogue 0 0 1 0
Cyproteron acetate + LHRH
analogue
0 0 1 0
LHRH analogue 0 0 2 0
LHRH analogue/Cyproteron Acetate 0 0 0 1
Gleason score
6 1 0 0 0
7 2 2 0 0
8 0 0 1 1
9 1 2 0 0
10 0 0 3 2
Initial PSA (ng/ml)
Mean 8.7 19.6 149.5 135.5
Range 5.3–13.0 8.5–38.0 6.5–511.0 17.0–254.0
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three therapy resistant tumors and three lymph node metastases
(Fig. 1). Androgen Receptor ChIP-seq was carried out on four primary
and three resistant tumors (Fig. 1).
1.2. Formaldehyde-assisted isolation of regulatory elements (FAIRE)
FAIRE was performed as previously described [2]. Brieﬂy, fresh fro-
zen tissues were cross-linked with 1% formaldehyde for 20 min. After
washing, nuclei were isolated as described before [3]. Afterwards chro-
matin was sonicated, cleared by centrifugation and subjected to three
consecutive phenol–chloroform–isoamyl alcohol (25:24:1) extractions.
Reverse cross-linking was performed at 65 °C overnight. Subsequently,
samples were treated with RNase A and proteinase K and puriﬁed by
using a PCR puriﬁcation kit (Roche).
1.3. Chromatin immunoprecipitation (ChIP)
Chromatin immunoprecipitationwas carried out as described before
[3,4]. 10 μg of AR-N20 (sc-618; Santa Cruz) antibody was used forFig. 1. FAIRE-seq and ChIP-seq analyses were performed on normal prostate tissue and
prostate cancer samples from different stages of the disease.immunoprecipitation, with 100 μl of Protein A magnetic beads
(Invitrogen).
1.4. DNA sequencing
Libraries were prepared according to Illumina DNA Sample Kit
instructions. Sequencing was performed on the Illumina HiSeq 2000
Genome Analyzer using 51-bp reads. Reads were aligned to the
Human Reference Genome (assembly hg19, February 2009) using
bwa 0.5.9.
1.5. Data analysis
Reads that map uniquely to the genome, with MAPQ quality
score above 20, were used for the analysis. FAIRE-seq and ChIP-seq
peaks were called with two algorithms, MACS 1.4 [5] and DFilter
1.0 [6], against mixed input controls corresponding to each group.
MACS was run with default parameters, except for p = 10−7 for
ChIP-seq data. DFilter was run with bs = 100, ks = 50 for FAIRE-
seq data and bs = 50, ks = 30, reﬁne, nonzero for ChIP-seq data.
Peaks detected by both algorithms were used for further analysis.
Sequencing read depths and number of called peaks can be found
in Table 2.
FAIRE-seq, ChIP-seq data and clinical annotation of the samples that
are deposited in NCBI GEO under accession number GSE65478.
For further analysis, a merged list of peaks present in all sam-
ples from each technique was generated. The number of peaks de-
tected by FAIRE-seq was 25,797, while 20,703 peaks were detected
by ChIP-seq. The AR binding sites had a median width of 350 bp
and peak size did not vary strongly with the largest peak size of
1202 bp (Fig. 2A). In contrast, FAIRE-seq peaks had a larger spread
in size with a median size of 255 bp. The largest peak size of
FAIRE-seq data was 2300 bp and a higher proportion of both
small and large peaks was present (Fig. 2A). The distance to the
nearest transcription start site (TSS) was determined by the
GREAT tool (http://great.stanford.edu/) [7]. The number of peaks
within 5 kb from the nearest TSS was signiﬁcantly higher in
FAIRE-seq data as compared to ChIP-seq data and the number of
peaks further than 50 kb from a TSS was higher in ChIP-seq data
than in FAIRE-seq (p b 10−15 Fisher's exact; Fig. 2B-C). This is in
accordance with AR binding mainly distant enhancer elements
[8], while accessible regions detected by FAIRE-seq include not
only enhancers, but also promoters [9].
2. Conclusions
In conclusion, we provide a unique dataset of genome-wide epi-
genetic proﬁling of prostate cancer tissue from different stages of
the disease. The dataset consists of two parts: accessible chromatin
proﬁling by FAIRE-seq and genome-wide androgen receptor binding
to DNA by ChIP-seq. We previously used this dataset to identify
changes in transcriptional regulation in prostate cancer upon acqui-
sition of resistance to hormonal therapy, as well as to derive a prog-
nostic gene expression signature for prostate cancer [1].
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Fig. 2. Comparative analysis of FAIRE-seq and Androgen Receptor ChIP-seq data. (A) Size distribution of peaks detected by FAIRE-seq and ChIP-seq in prostate cancer specimens. Pie charts
showing the percentage of peaks in categories based on the distance to the nearest transcription start site (TSS) in FAIRE-seq (B) and ChIP-seq (C) data.
Table 2
Sequencing and peak calling details.
GEO accession Experiment Tissue Total number of reads Mapped reads % mapped reads No. peaks
GSM1598204 FAIRE-seq Normal 19,147,127 17,986,187 93.94 50
GSM1598205 FAIRE-seq Normal 21,599,945 19,883,501 92.05 472
GSM1598206 FAIRE-seq Normal 26,080,719 25,043,481 96.02 61
GSM1598207 FAIRE-seq Normal 23,167,347 22,177,458 95.73 2837
GSM1598208 FAIRE-seq Primary 36,827,373 34,441,896 93.52 6450
GSM1598209 FAIRE-seq Primary 18,306,926 17,002,416 92.87 1579
GSM1598210 FAIRE-seq Primary 32,197,589 30,568,523 94.94 13,348
GSM1598211 FAIRE-seq Primary 28,992,853 27,590,961 95.16 2243
GSM1598212 FAIRE-seq Resistant 37,452,682 35,655,681 95.2 80
GSM1598213 FAIRE-seq Resistant 28,372,546 26,836,918 94.59 3497
GSM1598214 FAIRE-seq Resistant 27,545,618 26,061,843 94.61 5754
GSM1598215 FAIRE-seq Metastasis 39,562,972 37,594,752 95.03 2043
GSM1598216 FAIRE-seq Metastasis 29,130,845 27,291,106 93.68 281
GSM1598217 FAIRE-seq Metastasis 27,253,810 25,789,354 94.63 1313
GSM1598218 AR ChIP-seq Primary 13,782,549 12,232,556 88.75 754
GSM1598219 AR ChIP-seq Primary 18,146,927 16,009,388 88.22 402
GSM1598220 AR ChIP-seq Primary 13,040,014 11,254,994 86.31 17,511
GSM1598221 AR ChIP-seq Primary 9,928,626 7,080,840 71.32 3278
GSM1598222 AR ChIP-seq Primary 12,243,485 11,160,623 91.16 7932
GSM1598223 AR ChIP-seq Resistant 16,518,987 14,727,645 89.16 739
GSM1598224 AR ChIP-seq Resistant 16,382,421 14,441,817 88.15 238
GSM1598225 AR ChIP-seq Resistant 15,621,538 13,967,477 89.41 1779
GSM1598226 Input Resistant 28,171,838 26,825,849 95.22
GSM1598227 Input Metastasis 24,117,145 22,902,755 94.96
GSM1598228 Input Primary 23,982,305 22,739,491 94.82
GSM1598229 Input Primary 27,642,177 26,387,234 95.46
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